DMRA as reported
Damora Therapeutics, Inc. reported $8.2M of revenue over the trailing twelve months, +1541% on the year before. 8 reported series are charted on this page, each one as filed.
$8.2M
Revenue, trailing twelve months · to Q2 2026 · +1541% against the twelve months before
- Net Income
- −$263M
Net Income · +1484% year on year · trailing twelve months to Q2 2026
- Op Margin
- −7382%
Op Margin · trailing twelve months to Q2 2026
- EPS
- $7.49
EPS · −157% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $8.2M | +1541% | Q2 2026 |
| Net Income | −$263M | +1484% | Q2 2026 |
| EPS | $7.49 | −157% | Q2 2026 |
| Op Margin | −7382% | n/a | Q2 2026 |
| Net Margin | −7297% | n/a | Q2 2026 |
| ROE | −96% | n/a | Q2 2026 |
| ROA | −80% | n/a | Q2 2026 |
| Free Cash Flow | −$43M | n/a | Q4 2022 · 14 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Damora Therapeutics, Inc. (DMRA) - Revenue & ProfitRevenue & ProfitDamora Therapeutics, Inc. (DMRA)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com